BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26492180)

  • 1. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
    Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
    Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Profiles of Mixed Endometrial Carcinoma.
    Matrai C; Motanagh S; Mirabelli S; Ma L; He B; Chapman-Davis E; Kurtis B; Elemento O; Mosquera JM; Ellenson LH
    Am J Surg Pathol; 2020 Aug; 44(8):1104-1111. PubMed ID: 32604171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
    Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
    Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
    Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
    Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components.
    Rossi ED; Bizzarro T; Monterossi G; Inzani F; Fanfani F; Scambia G; Zannoni GF
    Hum Pathol; 2017 Apr; 62():99-107. PubMed ID: 28041971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
    Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
    Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
    Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
    Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed and Ambiguous Endometrial Carcinomas: A Heterogenous Group of Tumors With Different Clinicopathologic and Molecular Genetic Features.
    Espinosa I; D'Angelo E; Palacios J; Prat J
    Am J Surg Pathol; 2016 Jul; 40(7):972-81. PubMed ID: 26975040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted mutation analysis of endometrial clear cell carcinoma.
    Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial Adenocarcinomas With Significant Mucinous Differentiation: A Characterization of Intratumoral Heterogeneity of KRAS Mutations in Mucinous and Endometrioid Histologic Components.
    Jackson CL; Hang S; Hansen K; He M; Sung CJ; Quddus MR; Xiong M; Wang Y; Patel NR; Lawrence WD; Xiong J
    Int J Gynecol Cancer; 2018 Feb; 28(2):241-247. PubMed ID: 29303928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Despite Diagnostic Morphology, Many Mixed Endometrial Carcinomas Show Unexpected Immunohistochemical Staining Patterns.
    Matrai CE; Pirog EC; Ellenson LH
    Int J Gynecol Pathol; 2018 Sep; 37(5):405-413. PubMed ID: 29019871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences.
    Gatius S; Cuevas D; Fernández C; Roman-Canal B; Adamoli V; Piulats JM; Eritja N; Martin-Satue M; Moreno-Bueno G; Matias-Guiu X
    Pathobiology; 2018; 85(1-2):35-40. PubMed ID: 28614814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.
    Graham RP; Kerr SE; Butz ML; Thibodeau SN; Halling KC; Smyrk TC; Dina MA; Waugh VM; Rumilla KM
    Am J Surg Pathol; 2015 Oct; 39(10):1370-6. PubMed ID: 26099011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.